Why the study?
Does the selective GIRK activator ML297 prevent seizures in mouse models of epilepsy?
Does the selective GIRK activator ML297 prevent seizures in mouse models of epilepsy?
ML297 is the first potent and selective activator of GIRK1-containing channels and demonstrates significant antiepileptic activity in vivo, highlighting GIRK as a potential therapeutic target.
ML297's antiseizure activity in mice is hypothesis-generating; leaves open whether selective GIRK activation offers a viable human epilepsy target.
The G-protein activated, inward-rectifying potassium (K(+)) channels, "GIRKs", are a family of ion channels (Kir3.1-Kir3.4) that has been the focus of intense research interest for nearly two decades. GIRKs are comprised of various homo- and heterotetrameric combinations of four different subunits. These subunits are expressed in different combinations in a variety of regions throughout the central nervous system and in the periphery. The body of GIRK research implicates GIRK in processes as diverse as controlling heart rhythm, to effects on reward/addiction, to modulation of response to analgesics. Despite years of GIRK research, very few tools exist to selectively modulate GIRK channels' activity and until now no tools existed that potently and selectively activated GIRKs. Here we report the development and characterization of the first truly potent, effective, and selective GIRK activator, ML297 (VU0456810). We further demonstrate that ML297 is active in two in vivo models of epilepsy, a disease where up to 40% of patients remain with symptoms refractory to present treatments. The development of ML297 represents a truly significant advancement in our ability to selectively probe GIRK's role in physiology as well as providing the first tool for beginning to understand GIRK's potential as a target for a diversity of therapeutic indications.
No takes yet. Share an insight, caveat, or question.
Kaufmann et al. (2013) studied Epilepsy (n=49). ML297 (VU0456810) vs. Vehicle was evaluated on Prevention of convulsions in pentylenetetrazol (PTZ)-induced seizure model (p=0.006).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: